MS Australia's submission to the review of Australia's Disability Strategy draws on input form members of our LEEP and emphasises improving support for people with MS. Key recommendations include clearer goals aligned with global standards, increased workplace support, and meaningful involvement of people with disabilities through co-design. The submissions also advocates for accessible information and coordinated government action to address disparities in service delivery and ensure accountability.
MS Australia’s submission to the Inquiry into Aged Care Service Delivery highlights the urgent need for equity in aged care for older people with disability, including MS. It calls for immediate release of 20,000 home care packages, alignment of aged care funding with NDIS levels, and inclusion of disability-specific supports in the Support at Home program.
MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ocrelizumab (Ocrevus®) via subcutaneous (SC) delivery on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people living with relapsing-remitting multiple sclerosis (RRMS).
MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ublituximab (Briumvi®) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people living with relapsing remitting multiple sclerosis (MS).Â
MS Australia’s 2025-26 Pre-Budget Submission advocates for strategic investments to support over 33,300 Australians living with MS. Key funding asks include $8M for a National MS Biobank, $300M for a Neurological Research Mission, and $550K for neurological data improvements; $6.5M to expand MS nursing services, a national strategy, and training programs; Improved NDIS pricing, workforce, assistive technology, and income support; and Increased funding for disability-specific aged care services.
